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INTRODUCTION
Menstrual Regulation (MR), an interim method of establishing non-pregnancy for women who are at risk of becoming pregnant irrespective of whether conception has occurred or not [1] , was introduced in Bangladesh in 1970s as a strategy to reduce maternal morbidity and mortality associated with unsafe abortion [2, 3] . MR is usually conducted without a confirmatory pregnancy test, within 10 weeks of a missed menstrual period by paramedics and within 12 weeks of a missed menstrual period by medical doctors [2, 4] . The services are provided free of cost at primary, secondary and tertiary level public health facilities using manual vacuum aspiration (MVA).
However, women in Bangladesh face a range of barriers when accessing safe MR services that includes: high cost of MR at private hospitals and clinics, untrained private providers, inadequate equipments at some private facilities, and underlying social stigma [5] . Findings show that an estimated 26% of women seeking MR services each year are turned away by facilities due to various reasons, such as the woman's last menstrual period (LMP) limit exceeding the legal time limit for MR service provision, or provider bias when women have not yet had a child, are considered too young, or do not have their husband's consent [5] . In these circumstances, women are likely to resort to alternative methods of MR.
In light of this, there was a critical need to strengthen the national MR programme with a focus on policy and programmatic aspects to address the issues of inequitable access and to ensure quality of care. Following this, Bengali was developed and published in December 2013 [7] . The guidelines were designed to assist programme managers and service providers in better implementing the existing national MR policy.
The introduction of MR with medication (MRM) was the next step towards promoting women's equitable access to quality MR services in Bangladesh. Until 2012, manual vacuum aspiration (MVA) had been the only option for conducting MR in Bangladesh, yet this method is not suitable or acceptable to all women. In November 2013, based on evidence from a study conducted by icddr,b that indicated that MRM was a safe, acceptable alternative to MVA, the decision was made by the DGFP to introduce the drug combination of mifepristonemisoprostol for MRM into the country's national MR program [8] . This drug combination may be used within/up to 9 weeks of the woman's last menstrual period, is more discreet than MVA, and has fewer side effects [8] .
Following this decision, a memo regarding the approval of MRM in Bangladesh was circulated by the DGFP in Another 309 service providers from all primary, secondary, and tertiary level health facilities of Barisal division have also been trained by the government. In addition, staffs from all UH&FWCs from five districts of Khulna and Barisal divisions have been trained [9] . The DGFP is currently in the process of developing procurement agreements for the mifepristone-misoprostol combination pack in order to introduce MRM universally at public health facilities through Marie Stopes, Bangladesh and Population Council, Bangladesh with funding support from the Embassy of the Kingdom of the Netherlands (EKN) [9] . A number of local pharmaceutical companies currently manufacture the mifepristone-misoprostol combination while a few manufacture mifepristone alone.
Despite the significant progress that the government of Bangladesh has made towards introducing MRM into the national health program, there has been no systematic documentation on the introduction of MRM in Bangladesh, and on the approval process of local manufacturing of the mifepristone-misoprostol combination for MR. This research study was an initiative to document the entire process of introducing MRM in the country through a stakeholder analysis. In addition to the process documentation, a situation analysis and mystery client visit were conducted as part of this project to generate evidence on how approval of MRM has influenced the availability and provision of MR services through private pharmacies and medicine sellers in Bangladesh.
Figure 1: Walt and Gilson's Policy Analysis Framework
In this report, only the findings from the stakeholder analysis will be presented. The report is written following the policy analysis framework by Walt and Gilson, and has been categorized in four different parts: a) Context, b) Process, c) Content, and d) Actors.
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METHODS
Study Design:
The stakeholder analysis was conducted using a qualitative study approach. Semi-structured questionnaires were used to conduct interviews with the key stakeholders. Information was collected to explore the roles of different actors, the decision making process, and the contextual factors that led to the introduction and approval of MRM in Bangladesh.
Data Collection:
Two different data collection procedures were used:  A round table discussion was held with the similar key informants on 30 November, 2015 to discuss some of the issues and gaps identified during key informant interviews.
Categories of Key Informants:
 Policymakers from government and non-governmental organizations (NGOs) who were involved in the decision making of MRM introduction in the country and in its approval process.
 Implementers from government, and NGOs who were involved in implementing MRM services in the country.
 Pharmaceutical companies who were manufacturing the mifepristone-misoprostol combination pack locally.
 Medicine sellers who were involved in the promotion and sale of mifepristone-misoprostol combination for menstrual regulation.
 A random selection of mystery clients who participated in the situation analysis part of the study.
Selection Process of Study Participants:
 Review of existing literatures and listing of members of the MRM working group in Bangladesh.
 Brainstorming with the MRM working group members to identify more participants from various networks who participated in or supported the introduction, approval and implementation of MRM introduction in Bangladesh.
Figure 2: Key Informants Interviewed
Data Analysis:
Data analysis of the study was performed thematically. A transcript of each tape-recorded interview was prepared and then reviewed by a qualitative researcher to gain familiarity with the data and to highlight key issues, common ideas, and recurring concepts. The data was then systematically coded, indexed, and synthesized to enable interpretation of the findings. This entire work was done by a number of researchers to assess reliability of the data. Following this, key themes and sub-themes were identified by drawing attention to priority issues based on the aims of the study. Findings on the same issues discussed by various participants were compared to strengthen their validity and to assess their similarities and differences. Emerging themes and sub-themes were then analyzed to understand the potential roles of key stakeholders in the introduction, approval and implementation of MRM in Bangladesh. No specific qualitative data analysis software was used for the data analysis. 
Key Informants' Interviewed
RESULTS
Findings from the key informant interviews indicated some key factors that brought about the introduction of menstrual regulation with medication in Bangladesh, and are presented here following the four parts of Walt and Gilson's policy analysis framework: a) Context; b) Content; c) Process; and d) Actors.
a) Context:
Findings from the interviews with key stakeholders showed that introduction of MRM in Bangladesh were influenced by the following contextual issues:
 Some medicines, especially Gynaecosid (used to treat secondary amenorrhea) was easily available in local market that the women were using for regularize menstruation, if it was missed. This medicine was often imported from the neighboring countries that had unregulated sale in the local market by the medicine sellers. As a result, indiscriminative use of this medicine by the clients was increased.
 An increased incidence of complications due to usage of inappropriate medicines was revealed.
According to a study conducted in 2014, an estimated 257,000 women were treated for complications of induced abortions [10] which were found 231,400 in 2010 [5] .
 Performance of MVA by untrained providers and traditional healers in unhygienic environments caused high morbidity among many women. Many of these MVA procedures were incomplete and unsuccessful. Evidence showed that, roughly 120 out of every 1,000 MR procedures results in complications that are treated in health facilities in 2010 [5] .
 Complications from MVA likely result from improper use of MVA equipment, use of unsterile equipment, other unhygienic practices, and use of a MVA syringe more than the recommended 50 times [11] .
 The cost for MR procedures using MVA was relatively high. Safe and effective conduction of surgical MR using MVA required substantial investments in adequately trained and skilled personnel, wellequipped and private MR procedure rooms, clean and sterile instruments, logistics, and medications in proper dosage.
 Economic, cultural and social barriers limited women's access to safe MR services using MVA.
Women's fear of undergoing a surgical procedure and privacy concerns related to the social stigma of MVA often discouraged them to seek the service within the legal time limit, which in turn caused a higher number of rejections. Evidence also showed that women identified social stigma and fear of the procedure as the main obstacles to seeking safe MVA services [12] .
 Many women were unaware about the information regarding safe surgical MR provision by MVA, such as from where to seek these services, and about the legal time limit of MR service provision by MVA.
 Due to lack of awareness of the magnitude of risks related to unsafe MVA, women often sought services from untrained providers and consequently suffered from complications which sometimes lead to death.
 Although MVA is safe procedure, it is invasive and carries risk of complications; a non-invasive, more suitable, technologically simple, and easy-to-use alternative method of MR was desired by both women and providers.
b) Process:
Since 1980's, Gynaecosid as well as other medicines were being used for regulation of menstruation in Bangladesh. These medicines were available in local pharmacies and were easily accessible to the community.
Yet due to lack of awareness about safe MR service provision, unregulated sale, and indiscriminative use of these medicines, high rates of maternal morbidity and post-MR complications were happening widely.
Stakeholders from different NGOs, programme implementers, as well as professional bodies saw the acute need for a solution to this situation. They planned to develop a policy guideline to control the unregulated sale and rampant misuse of these medicines.
In 2002, mifepristone -a medicine that brings on a period -received approval in India for the purpose of using for menstrual regulation. Following that, there was a growing interest among Bangladeshi stakeholders to introduce mifepristone for MR in Bangladesh. In 2004, the WHO launched safe abortion guidelines through a workshop held in Bangkok, where two representatives from Bangladesh were present. Soon after their return, these representatives submitted a proposal to the National Technical Committee (NTC) of the Directorate General of Family Planning (DGFP) to introduce menstrual regulation with medication (MRM) in Bangladesh [13] . However, the committee expressed their concerns about the possible side effects of MR medicines, and suggested to think strategically before submitting any further proposal on MRM.
i) Formation of MRM Working Group:
Advocacy Foundation, discussed the relevance of MRM and introduction of the combination of mifepristone-misoprostol for MR services in Bangladesh [14] .
During the seminar and roundtable, one of the leading personnel from Obstetrics and Gynecological Society of Bangladesh (OGSB) did informing about the approval of MR medicines in some of the developed countries like USA and Europe, and also about the ongoing trials on MRM in Nepal. The discussion yielded an overall consensus that MRM can be introduced in Bangladesh as an alternative to MVA [14] . Yet some key stakeholders expressed their concern that introduction of MRM would raise debate around MR services in the country --most importantly, the sensitivity of MR issue in Bangladeshi society and possible negative public reactions toward MRM introduction. They also underscored the need for organized and careful steps to introduction. Based on the discussions, comments, and suggestions, and to implement the consensus of the roundtable participants to explore the use of MRM in Bangladesh through research, three initial steps were recommended:
Step 1: Review international experiences with MRM.
Step 2: Prepare for research on mifepristone and misoprostol in Bangladesh; and
Step 3: Conduct clinic-based research.
ii) First Trial on MRM in Bangladesh:
In 2008, the combined regimen of mifepristone and misoprostol, Medabon ® , were nationally approved and registered for medical abortion and use in public health facilities in Nepal [15] . Simultaneously, mifepristone- The objective of conducting the trial was to assess women's and providers' acceptability and feasibility of simplified mifepristone-misoprostol combination regimen for menstrual regulation [16] . Findings from the study showed that the combination drug for MR was highly acceptable to women; the majority of the participating women (93 percent) chose to obtain MR through MRM and most of them (92 percent) were satisfied with this procedure. Providers faced initial challenges and concerns, particularly about additional counseling requirements and lack of control over the final outcome, but became more confident after successful use of the proper regimen of the combined medicines [16] . The study recommended that mifepristone-misoprostol combination can safely be offered within the existing menstrual regulation services system in urban and periurban areas in Bangladesh. The trial also acted as a platform to increase providers' knowledge and interest in this approach and in creating a group of "Local Experts" [10] .
In November 2010, a dissemination meeting on the above study findings was held in Dhaka, where the stakeholders expressed their satisfaction related to MRM [17] . Simultaneously, some of them also raised concerns regarding indiscriminative use of MR medicines due to unregulated management of the drug sellers, easy accessibility of MR medicines to the clients, and the capacity of government service providers to provide MRM services. Apart from these concerns, the stakeholders agreed to move forward for MRM approval in
Bangladesh [17] .
iii) Further Trial on MRM at Public and NGO Health Facilities:
With In January 2011, in its 57 th meeting, the National Technical Committee (NTC) at the DGFP asked the relevant stake holders to conduct pilot studies on 'MRM in public sector health facilities' [18] . In response to this Bangladesh. This study offered mifepristone and misoprostol combination for MR to the clients and finally was able to enroll 1,744 women who received the combined medicines for MR services from the selected facilities [20] . Findings from the study showed that most women (96.3%) had a successful uterine evacuation without the need for a surgical intervention. [20] .
Another study was conducted between April and October 2013 by the OGSB in collaboration with the DGFP with support from World Health Organization [21] . The study was implemented in five purposively selected health facilities in Dhaka city. Women who came for MR were given the opportunity to choose either MVA or MRM with mifepristone-misoprostol combination. In that study, 500 women received the combined regimen of mifepristone and misoprostol to establish their menstruation. Among them 69.11% returned for follow up visit and checkup. Findings from the study showed that, 7.74% of the women with mifepristone and misoprostol combined regimen did not get the expected result of the medicines and they had to go further for MVA or to be referred for dilatation and curettage (D&C/MVA) services to establish their normal menstruation [21] . 
MRM Working Group
iv) Approval Process for Local Manufacturing of MR Medicines:
In 2008, misoprostol was approved in Bangladesh for the treatment of postpartum hemorrhage (PPH).
Evidence from other countries had also shown that misoprostol could be used for early termination of pregnancy [22] . Simultaneously, a combination of misoprostol and mifepristone had been shown to work even more effectively, and was found to be acceptable and feasible for conducting MRM in Bangladesh [16] .
However, mifepristone was not an approved and registered medicine by the Directorate of Drug Administration (DGDA), Bangladesh; therefore, separate approval was needed for mifepristone and the combination of mifepristone-misoprostol to introduce these combination medicines for use in MR in the country.
 Step 1: Approval of Mifepristone
The MRM working group played a vital role in the process of approval of local manufacturing of mifepristone.
On behalf of the MRM working group, the president of Obstetrical and Gynecological Society of Bangladesh (OGSB), initiated the process of registering mifepristone and requested several pharmaceutical companies to manufacture it locally. As a result, one of the pharmaceutical companies took the initiative to manufacture and register mifepristone.
The MRM working group co-opted the pharmaceutical company as working group member. However, approval from the DGDA was needed prior to manufacturing and marketing this new medicine in the country. As a primary step to this, and to facilitate the process, a written proposal was submitted to the Technical Sub-Committee (TSC) of the DGDA, which gives approval of any new medicines to be manufactured in the country.
A formulation of the medicine (including international references), and findings from the completed research studies on trial of the medicine were also needed to submit with the proposal. International references were taken from United States Food and Drug Administration (USFDA), and British National Formulary (BNF). Trial findings were collected from the research study titled "Acceptability and Feasibility of mifepristone-misoprostol for Menstrual Regulation in Bangladesh", conducted by icddr,b and was a joint collaboration between icddr,b
and Gynuity Health projects [16] .
The pharmaceutical company submitted the formulation of the medicine along with all necessary documents and evidence to the TSC if the DGDA to receive approval from the Drug Control Committee (DCC). Finally, on 13 September, 2012, mifepristone was approved by the Drug Control Committee (DCC) to be manufactured, sold, and administered locally [23] . The entire process took approximately a year from the date of submission of the documents by the pharmaceutical company to the TSC until its final approval.
 Step 2: Approval of Mifepristone-Misoprostol Combination Pack
After receiving approval of mifepristone only, the MRM working group initiated the process of approval of local manufacturing of mifepristone-misoprostol combination pack for MR. A combination pack was a specific focus of the approval as it was identified as a way to prevent indiscriminate or incorrect use of the medicines when those were used separately. The apprehension was that, if mifepristone and misoprostol were dispensed in separate packets, users may use only one of them which would decrease the effectiveness and eventually lead to increased incomplete MR, which is a health risk for women. This concern was already aggravated by existing over the counter sale of MR medicines by medicine sellers. It was not an easy task for the relevant stakeholders to get approval of the mifepristone-misoprostol combination pack from the Technical subcommittee (TSC) of the Directorate General of Drug Administration (DGDA). The TSC retained several concerns:
 MR is a socially sensitive issue in Bangladesh.
 MR related complications may increase due to incomplete MR or method failure resulting from irrational or improper use of the drugs.
Members of the MRM working group, especially the obstetricians and gynecologists, exerted much effort in advocating for the combination pack of mifepristone and misoprostol and in convincing the DGDA to approve this. They emphasized that though sensitive, but MR has been an approved service in Bangladesh since 1979, was introduced as a backup for ineffective use of contraceptives, and that MRM is in fact a safer and effective alternative method to MVA for conducting MR.
To encourage the TSC to recognize these facts and approve MRM, one of the pharmaceutical companies presented them with evidence from the pilot study on MRM at NGO sector health facilities conducted by icddr,b, which was the only completed study at that time that revealed the findings on the feasibility and acceptability of MRM in Bangladesh [16] . It was unusual for the DGDA to request recommendation letters in favor of a particular medicine from any authority as a precursor to approval. However, because the mifepristone-misoprostol combination does include abortifaecient medicines, and since abortion is a legally restrictive and sensitive issue in Bangladesh, the DGDA requested the letters prior to approving the drug as an additional layer of scrutiny.
In February 2013, the culmination these efforts finally brought success and the pharmaceutical company received approval of the mifepristone-misoprostol combination for MR to manufacture, sell, and administer it locally [24] .
 Challenges during getting approval for manufacture, sell, and administration of MR 
medicines, and MRM policy formulation
During getting approval for manufacture, sell, and administration of MR medicines, and MRM policy formulation, following issues and concerns raised among relevant key stakeholders:
 Inappropriate or improper use of MR medicines by clients;
 Indiscriminate or random use/sale of MR medicines by medicine sellers, and local service providers;
 Whether there would be a delay in receiving approval of the MR medicines from the DGDA and other drug regulatory and approval authorities considering the restrictive law and social barriers to abortion in the country.
c) Content: i) Integration of MRM in National MR Program in Bangladesh
The National Technical Committee (NTC) of Directorate General of Family Planning (DGFP) approved MR with mifepristone-misoprostol combination at its 61 st meeting held on 26 November, 2013 [25] . The next priority task was to formally integrate MR with mifepristone-misoprostol combination into the National MR program.
During that time (from January 2012 to June 2013), an operations research study "Introducing Medical Menstrual Regulation in Bangladesh" was conducted by the Population Council in collaboration with Marie Stopes Bangladesh and the DGFP in public facilities and NGO facilities providing MR services [19] . The aim of the study was to test the feasibility of introducing MRM in Bangladesh as well as to assess the accessibility of mifepristone and misoprostol combination in health facilities of Bangladesh [19] . Findings of the study revealed that of the 2,976 women who sought MR services in health facilities, 63% of them selected MRM when offered a choice between MRM and MVA [18] . Women who choose MRM over MVA indicated following reasons for choosing this option:
 Less expensive (52%),  Did not require any surgical intervention (34%), and  Perceived it as less risky (29%) [19] The study also included observations of MR service providers were in order to assess the quality of their service delivery. Findings showed that the overall quality of services for MRM was high; two-thirds of the women who received MRM services from the health facilities were satisfied with the process of MRM and quality of care provided by the service providers [19] . The evidence from this study indicated that introducing the study helped relevant actors to take the initiative on integrating MRM into the national MR program [19] .
In February 2015, DGFP circulated a memo regarding the approval of MRM in Bangladesh. This circular stated that within 6-9 weeks of women's last menstrual period, 200 milligrams of mifepristone and 800 micrograms (4 tablets of 200 mcg) of misoprostol may be used for MR [4] . For the most effective result, at first, 200 mg tablet of mifepristone should be taken orally followed by of the 800 micrograms of misoprostol in 24 hours, either buccally, sublingually, or vaginally [4] . In addition, the memo also indicated that MR service providers should receive proper training on MRM service delivery prior to providing this service to their clients [4] .
ii) Development of MRM Guidelines
Findings from this stakeholder analysis revealed that in order to train and educate service providers and to provide consistent information among different cadres of service providers, development of a precise service delivery guideline for administering MRM was essential. It was understood by the government and the stakeholders who were already involved in MR service provision. 
 Availability of Medicines for MRM in Bangladesh
To document the availability of MRM medicines in Bangladesh, key informant interviews were conducted with two different groups of respondents including medicine sellers and mystery clients. Since survey responses do not always reflect real-life practices, mystery client encounters were utilized in the 'Situation Analysis' part of this study to assess the actual provision of mifepristone-misoprostol combination regimen by the medicine sellers. The mystery clients were field research team members who were specially trained to give standardized responses during their interaction with the medicine sellers. The purpose of conducting interviews with medicine sellers and mystery clients was to collect information on availability, cost, and supply chain mechanism of mifepristone-misoprostol combination regimen in local pharmacies.
Information provided by medicine sellers and mystery clients revealed that cost of available medicines for MR in the market ranges from 15 taka to 300 taka (BDT) (equivalent to $0.20 to $3.80 USD). Findings from mystery client interviews indicated that cost of medicines usually does not discourage the women from purchasing them because of their prevailing desire to restore their normal menstrual cycle and overcome a crisis situation.
The medicine sellers often capitalize on this emergency situation of the clients by asking for a higher price than is appropriate. Two main reasons that motivate women to purchase particular MR medicines were the effectiveness of the particular medicine and women's ability to afford the drug. Mystery client interviews also revealed that not only did the price vary from seller to seller, but so too did the medicine sellers' approach toward the clients vary with different contexts. Seller attitudes varied on topics such as duration of pregnancy and marital status of the clients.
Among all available MRM medicines, MMKit and MTP Kit (mifepristone-misoprostol combination regimen); cytomis and isovant (misoprostol only); and MIF (mifepristone only) were identified by the medicine sellers as the most popular and commonly used medicines. However, emergency contraceptive pills were erroneously identified as MR medicines by some of the medicine sellers.  Motivation of women for MRM: Medicines for MR work comparatively slower than manual vacuum aspiration, and usually takes from 24 hours to three days to work. This sometimes discourages women to seek MRM services, especially those who are from lower socio-economic conditions and live on daily wages, as they don't want to lose their wages for a longer period than necessary. The slow process of performing MR with medicines is a barrier to women's motivation to seek MRM services.
ii) Supply Side Challenges
 Inadequate knowledge and practice of the informal providers (including medicine sellers, village doctors, homeopaths, and Kobirajs) regarding MRM: Due to informal providers' having
improper knowledge of appropriate MRM counseling and complication management, many women suffer from incorrect use of medicines for MR and related complications.
 Indiscriminate and unregulated sale of MR medicines by medicine sellers: Informal
providers do not properly screen clients prior to providing MR medicines to them. Moreover, they sell MR medicines without any prescription and without providing women with any counseling.
Findings showed that medicine sellers provide MR medicines to the clients beyond the legal time limitation of MRM (up to 9 weeks of gestational age). They were seen to provide medicines for MR even if the women had reached 13 weeks of pregnancy. 
e) Areas for Further Improvement
The participants who took part in this stakeholders' analysis suggested some areas of further improvement for sustainability of the MRM program in Bangladesh. These suggestions were provided from two different perspectives:
 to meet demand-side (client-side) barriers o Supply of MRM medicines at public health facilities to make them available to women who do seek services.
ii) To Resolve Supply Side Barriers
 Build awareness among frontline health workers or service providers about MRM: informal service providers such as medicine sellers, village doctors, homeopaths, and kobirajs need orientation and training on MRM (especially on counseling, proper use of MR medicines, side effects of MRM and complication management.) These frontline service providers are most often the primary contact person for women when seeking health care services for culturally or socially stigmatized health issues including MRM. Due to inadequate knowledge on MRM and its related issues, informal providers (especially medicine sellers) often provide these medicines without adhering to any regulation which ultimately can cause health complications for women.
 Stop providing separate packets of mifepristone and misoprostol for MR: pharmaceutical
companies should stop providing mifepristone and misoprostol for MRM separately to the medicine sellers and should promote the combination regimen packs. This is because offering the medicine in separate single packs increases the likelihood that clients will purchase and use a single MR medicine (i.e. either misoprostol or mifepristone alone for MR) which decreases efficacy and increases the risk of incomplete MR.
 Allocate incentives for the trained providers who are authorized to provide MRM services:
According to some participants interviewed, often providers are reluctant to provide MRM services because they do not earn any remuneration by providing this service. Meanwhile, they do get remuneration for performing manual vacuum aspiration (MVA). Arranging remuneration for the trained MRM service providers may motivate them to offer both services with equal emphasis.
 Develop strong monitoring and supportive supervision system: Develop a strong monitoring and supportive supervision system to oversee service providers' practices in accordance with the national MRM guideline [26] and to control the unregulated sale of MR medicines by the medicine sellers.
 Develop a one-stop service mechanism: Set up a one-stop service mechanism in health facilities with trained MR service providers; ensure adequate supply of MR medicines and logistics in facilities; make provisions for complication management and availability of referral facilities.
 Build capacity and resource utilization: Increase the number of field staff with adequate knowledge and training on MRM.
 Improve record-keeping systems: Establish a proper and improved reporting system to maintain register books for MRM service provision and documentation. 
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